Activity and Safety of Second Line SOrafenib After Pazopanib in Patients With Metastatic Renal Cell Carcinoma (SOAP Study)

Trial Profile

Activity and Safety of Second Line SOrafenib After Pazopanib in Patients With Metastatic Renal Cell Carcinoma (SOAP Study)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Sorafenib (Primary) ; Sunitinib (Primary) ; Pazopanib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms SOAP; TOKIO
  • Most Recent Events

    • 21 Nov 2017 Status changed from recruiting to discontinued.
    • 25 Aug 2017 Planned End Date changed from 1 May 2016 to 1 May 2018.
    • 25 Aug 2017 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top